|

SGLT2 inhibitor Clinical Trials

7 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Canagliflozin, Invokana, canagliflozin, dapagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin +2 more

Pipeline

Phase 4: 3

Top Sponsors

  • University of Michigan1
  • Samsung Medical Center1
  • Kiyuk Chang1
  • Kafrelsheikh University1
  • Chong Kun Dang Pharmaceutical1

Indications

Other5 trials

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients
Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
Phase 4
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Huntsville, Alabama1 trial

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Longwood Research LLC

Phase 4

Ann Arbor, Michigan1 trial

Mechanism of SGLT2 Inhibition in the Kidney

University of Michigan

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.